These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 31707573)

  • 1. Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety.
    Ponzani P; Berra C; Di Lelio A; Del Sindaco P; Di Loreto C; Reggiani F; Lucisano G; Rossi MC
    Diabetes Ther; 2020 Jan; 11(1):97-105. PubMed ID: 31707573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety.
    Ponzani P; Berra C; Di Lelio A; Del Sindaco P; Di Loreto C; Reggiani F; Lucisano G; Rossi MC
    Diabetes Ther; 2018 Dec; 9(6):2209-2218. PubMed ID: 30242611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study.
    Laviola L; Porcellati F; Bruttomesso D; Larosa M; Rossi MC; Nicolucci A;
    Diabetes Ther; 2021 Feb; 12(2):509-525. PubMed ID: 33351177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.
    Landstedt-Hallin L; Gundgaard J; Ericsson Å; Ellfors-Zetterlund S
    Curr Med Res Opin; 2017 Apr; 33(4):647-655. PubMed ID: 28035840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2).
    Miura H; Sakaguchi K; Okada Y; Otowa-Suematsu N; Yamada T; So A; Komada H; Hirota Y; Kishi M; Takeda A; Tominaga Y; Nakamura T; Kuroki Y; Matsuda T; Iida K; Kajikawa M; Ohara T; Yokota K; Hara K; Tateya S; Tamori Y; Ogawa W
    Diabetes Ther; 2018 Dec; 9(6):2399-2406. PubMed ID: 30341665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes.
    Henao-Carrillo DC; Muñoz OM; Gómez AM; Rondón M; Colón C; Chica L; Rubio C; León-Vargas F; Calvachi MA; Perea AM
    J Clin Transl Endocrinol; 2018 Jun; 12():8-12. PubMed ID: 29892561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.
    Melzer Cohen C; Thorsted BL; Wolden ML; Chodick G; Karasik A
    Diabetes Ther; 2017 Oct; 8(5):1047-1055. PubMed ID: 28884311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study.
    Fadini GP; Giordano C; Salvi L; Nicolucci A;
    Diabetes Ther; 2020 Dec; 11(12):2909-2920. PubMed ID: 33011923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes.
    Predieri B; Suprani T; Maltoni G; Graziani V; Bruzzi P; Zucchini S; Iughetti L
    Front Endocrinol (Lausanne); 2018; 9():462. PubMed ID: 30190702
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study.
    Conget I; Mangas MÁ; Morales C; Caro J; Giménez M; Borrell M; Delgado E
    Diabetes Ther; 2021 Nov; 12(11):2993-3009. PubMed ID: 34599749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
    Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial.
    Iga R; Uchino H; Kanazawa K; Usui S; Miyagi M; Kumashiro N; Yoshino H; Ando Y; Hirose T
    Diabetes Ther; 2017 Aug; 8(4):783-792. PubMed ID: 28547206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
    Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
    Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
    Wiesli P; Schories M
    Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of switching from insulin glargine to insulin degludec in patients with type 1 diabetes: a 16-week retrospective study.
    Suzuki J; Yamakawa T; Nagakura J; Shigematsu E; Kadonosono K; Terauchi Y
    Diabetol Int; 2017 Mar; 8(1):45-51. PubMed ID: 30603306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.
    Kaku K; Wolden ML; Hyllested-Winge J; Nørtoft E
    Diabetes Ther; 2017 Feb; 8(1):189-195. PubMed ID: 28091878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study.
    Harris SB; Ajala O; Bari B; Liutkus J; Hahn J; Martyn O; Zwicker D
    Diabetes Ther; 2021 Jun; 12(6):1689-1702. PubMed ID: 33932223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.
    Suzuki J; Yamakawa T; Oba M; Nagakura J; Shigematsu E; Tamura H; Takahashi K; Okamoto Y; Sakamoto R; Shinoda M; Takano T; Kadonosono K; Terauchi Y
    Endocr J; 2019 Nov; 66(11):971-982. PubMed ID: 31270291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Cost Implications of Insulin Degludec in Patients with Type 1 Diabetes and Problematic Hypoglycemia: A Quality Improvement Project.
    Karamat MA; Dar S; Bellary S; Tahrani AA
    Diabetes Ther; 2018 Apr; 9(2):839-849. PubMed ID: 29549574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy.
    Langer J; Wolden ML; Shimoda S; Sato M; Araki E
    Diabetes Ther; 2019 Aug; 10(4):1347-1356. PubMed ID: 31168694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.